following two mrna immunizations regardless of the variant. if you look at the horizontal access, and b-29's when you get your second shot. you can see the level of antibodies go up at 43 days. look what happens at 119 and 209 days. regardless of the variant involved, the antibody level against those variants declined over time. next concept, that higher levels of antibody are associated with higher levels of vaccine efficacy. is often referred to as an immune carl it -- this was published in a recent server. it shows a model of vaccine efficacy, this case based on the moderna three trial, showed four weeks after the second dose, what you have is a neutralization titer of one to 100 which goes up from the vertical redline. that gives you any quick to see that that gets you in efficacy of 91%. if you look at the black line from left to right, as you go further up you have a higher degree of efficacy. the higher the neutralization titer, the higher degree of efficacy. third issue, higher levels of antibody may be required to protect against delt

announcement and your assessment of the data behind that announcement on the effectiveness of the mrna vaccines and whether they are waning over time? guest: it is great to be here. there is a lot of covid news. what we heard yesterday is the administration is planning to roll out boosters for everyone in america who received one of the mrna vaccines -- the moderna and the pfizer vaccine. they are making those plans due to data from the u.s. and overseas. the studies that were released here in the mmwr, a publication the cdc puts out, shows a couple things. on the good news front, the study shows the vaccines remain extremely effective at preventing hospitalization, which is really what we designed the vaccine to do, to prevent severe infection, hospitalization and death. that has held up really well. what some of the study showed, however, is the protection against overall infection goes down. it is not clear from these studies whether it goes down because of a dropping level of protecting factors over time, or because of the new variant that is now -- it accounts for more than 90%, t

if people want the mrna vaccine, we will do that. we have the menu and it's available. >> what would you say to people who are tired of wearing masks and being [inaudible] ? >> well, i'm disappointed that the health office, i'm sorry that we had to go to indoor masking as well. it's the right thing to do in terms of where we are right now. especially, our projections are showing cases are going to continue to increase through this month and early september, so we really need to slow down the transmission. what i would say if you're tired of wearing a mask, if you're not vaccinated, for god's sake get vaccinated and get your family and friends vaccinated. >> had is there an now that this delta variant is surging and it is so much more contagious, a lot of those sites, they've shut down? >> so we're continuing to work with our other health partners across the city to ensure there's adequate testing for people. d.p.h. has been doing over 40% of the tests that have been administered. so just to emphasize that piece working with kaiser an

they say we could see a lot more uses of this mrna technology. the future in san francisco to lead the psac ii kron 4 news. >> sometimes they feel like back to a 100%. so and sometimes i feel like i'm a quarter percent of myself. >> still ahead, a lengthy battle with covid and an even longer recovery. this bay area survivor shares. his story will have that. up next. >> we'll check out what san francisco animal control and pulled out of the bay. they spotted this coyote pup in the water near pier. 39 one of the animal control officers borrowed a boat in grabbed the coyote. she was warmed up under a heated blanket and treated for hypothermia been released and she's a cutie pie and maybe now that she's act out. >> in the air and in the weather for today, john. >> we're looking at what she's going experience after going to that little ordeal. what can we expect have. well, she looks like she's nice and warm in that blanket for sure. it is going to be warm outside that blanket too. >> as we do look at conditions out there today. so hot across the bay

the booster mrna immunization increases antibody titers by at least tenfold. these are data from moderna, but pfizer has announced very similar data. the bottom line is, if you look first at the left panel, the first column is looking at the antibody titers just before the third dose and then 15 days after the third dose is shown right next to it that says d15. as you can see, a remarkable increase in titers against the 614g, the b1351, the p.1 and the pfizer data which you would suspect to be similar to the moderna, is also against the delta variant. you get a dramatic increase in antibody tighters when you do a third immunization dose. last slide. so in summary, the current immunological data that indicate that antibody levels decline over time, higher levels of antibody are associated with a higher level of efficacy, higher levels of antibody may be required to protect against delta and, as i showed you on this former slide, a booster mrna immunization increases antibody titers by multiple-fold. all of this support the use of a third booster mrna immunizati

. >>> businesses program themselves like you would program a computer so if you had an mrna vaccine, a piece of code, it is atc's and g's not zero and ones, but they make a protein and turn your music on. >> that is jason kelly founder and ceo of ginkgo bio works, a company slated to go public via spac toward the end of the year with participation of kathy woods arc invest biotech break-throughs were front and center in 2020 for a race for a vaccine for the covid-19 and advances are also continuing in gene therapy and cancer and neurology and rare diseases and more. the next guest is an analyst, ali irwin is specializing in technologies welcome. just want to start with gene editing first. you could give us a sense of what is on the frontier with regard to gene editing when i think of that, i think of immortality. is that something that is possible with the exception of getting hit by a car or other things will we be dying from diseases in the future thanks to gene editing? >> so, the short answer is, you know, not immortality in the short-term for sure but we may be able to create cu

so all these different types of covid—i9 vaccines, whether it is mrna or other types, all the dna type robust immune response.- which is eliciting a robust immune response. 0k, ithinkl 'ust immune response. ok, ithinkl just about— immune response. 0k, ithinkl just about followed _ immune response. 0k, ithinkl just about followed the - immune response. 0k, ithinkl just about followed the science | just about followed the science of it. what is the advantage of this method as opposed to others? ., this method as opposed to others? . ., others? there are a few advantages. _ others? there are a few advantages. it - others? there are a few advantages. it is - others? there are a few| advantages. it is stable, others? there are a few. advantages. it is stable, it others? there are a few- advantages. it is stable, it is relatively inexpensive to produce, it also has a good storage component so you don't have to use ultra cold storage requirements like for example the mrna based vaccines, it is easier to produce. these are all the various different benefits of using a dna —based vaccine. benef

moderna which is a company founded on the promise of mrna was going that route the entire time a lotely in the early days on this work, guys. >> i can't wait to watch it, meg. because you're wondering what was going on behind the scenes as these companies shifted their business, their resources, and their money into this effort and the question now about the promise of mrna and just what could come next when it comes to this new technology that was put to work and quite successfully where do we go from here >> yeah, that is another thing that we get into in the documentary. some of the opportunities are in things like flu vaccines, can mrna deliver us better seasonal flu vaccines and then beyond that, biontech was using cancer drugs before this so they have to turn the ship completely and that is a big area for mrna as well. >> meg, thank you very much. and be sure to catch meg's documentary a race against covid that is available now on cnbc and on youtube >>> up next, your wall street look ahead zoom video is gearing up for results next week and investors are looking for clues how t

decades earlier to develop an mrna molecule that could be used as a vaccine. -- as an immunogen for a vaccine. in addition, the vector-based approach, such as the one that j&j did, was again done 10-20 years earlier with hiv. and the very elegant work of the development of an immunogen that would be highly immunogenic, to get the kind of high efficacy and effectiveness that we got, was work done at the nih vaccine research center. and by many of our grantees -- grantees over 1-2 decades. when people say, i'm concerned that this went too fast, it did not go too fast, it was a major investment, both in logistics, the resources, and the clinical and basic research. so, i'll hand it now back to you, jeff. >> i will hand it over to dr. murphy. dr. murphy: thanks so much, jeff. it's great to be with all of you again this morning. we all know cases have risen across the country due to the delta variant. there are americans wondering what this really means to them and their families. i want to emphasize one fact that remains true. that is that the vaccines are working against the delta vari

we are going to need mrna vaccines -- mrna vaccines have the advantage of being able to scale up production the traditional method for the astrazeneca vaccines. there is also the price to consider. in many low income countries only 1.1% of their populations have been fully vaccinated. this is the majority of the world where high levels of population densely living in close porters with high levels of community transmission, low vaccine coverage, and a week health system. it is a recipe for a new variant to emerge. as long as we can get a blend of those vaccines that suits that content out there as soon as possible, and i think the biden administration has done the right thing to back the waiver on this for ip restrictions, then we are looking at the best long-term use. i do not think we need to nitpick to that degree. a jab that we can get as many people as possible coverage should be the priority, not which strand -- not which brand. guy: the brand issue is important to a certain extent inasmuch as are we at the point where it would be better to give those that have had astra and mrna vacc

a very big part of moderna's future will be in being the leading vaccine developer with mrna technologybut also additional new technology we are considering to augment that capability. i should also say within the broader pioneering context, we have multiple projects as well looking to expand the security net for future pandemics. ♪ ♪ david: as we talk today we are in boston and it is probably not a surprise many people would say people from m.i.t. or harvard were involved in moderna. but your background is different than many people at m.i.t. and harvard. you did not grow up in this country, is that correct? noubar: that's right. i was born in beirut, lebanon of armenian parents. lived there until the civil war in 1975, and ended up escaping the civil war and growing up in montreal, canada. david: you were a teenager when you went to canada. noubar: i was extremely fortunate. my family, they took us as political refugees. david: you went to mcgill university. what did you major in? noubar: chemical engineering. which was an interesting field at the time, because that is the field that

>> the two mrna vaccines, the pfizer vaccine and the moderna vaccine, are essentially identical in my mind, and they're probably the best vaccines we have right now in terms of efficacy against the delta variant. the data on johnson & johnson is just much less clear. there is enough data out there in my mind to suggest that the j&j vaccine is still going to do a very, very good job of protecting against severe illness and death. the question is, how good a job is it going to do against preventing breakthrough infection, symptomatic infections? and the short answer is we just don't know, and we'll know more in the upcoming weeks. the thing that i worry about are the chinese vaccines, which have been used maybe about 1/3 to 1/2 of all the vaccines in the world so far have been the vaccines made in china. again, we don't have a lot of data on them, but the data we have suggests that they're far, far less effective against the delta variant. that worries me, because it means a lot of the world that's been vaccinated is actually potentially quite still vulnerable to the delta variant. >>ou

they had a third dose of one of the mrna shots that the third shot showed a significant increase in theibodies. so, there has been, and it is consistent with other evidence that an additional shot does seem to invigorate the immune system in a way that does seem to be positive. we do not have proof of this yet . we do not have huge numbers for the data and it is not approved, but it does make sense and the research would suggest that it is something that we really should think about. >> and just today they okayed it or suggested or mandated that? >> it is suggested. it came to the medical executive committee for approval as to whether or not to approve. so far looks like it will be unanimously approved. those that got to the j&j shot get an additional, or are approved to get an additional mrna shots, either pfizer or moderna. it is not mandated. it is not clearly data-driven yet, but the data does support this. >> you will be turned away? if you're just a regular person and you supply your information and you are ready in the database, i know some people. >> as of today. >> you think th

calling on the biden administration to adopt a wartime footing to massively increase the availability of mrna vaccines around the world. the scientists warn -- "without urgent and immediate scale up of vaccine production and distribution, millions more will be infected and die." in the united states, the centers for disease control is recommending that pregnant people get vaccinated against covid-19. the cdc said wednesday it found no evidence the vaccines increased the risk of miscarriage. meanwhile, the food and drug administration is poised to authorize a third dose of vaccine for people with weakened immune systems, such as cancer patients and those who have undergone organ transplants. the world health organization recently urged wealthy nations not to authorize booster doses until 10% of people in every country have had access to a vaccine. florida's health department has asked the federal government to ship 300 ventilators, as hospitals are overrun with covid patients in one of the worst coronavirus outbreaks in the wod. florida republican governor ron desantis continues to resist -- p

they say we can expect to see this mrna technology for many uses of the future. for now live in san francisco. to that, key kron 4 news exciting science art taylor, thank you for that. meanwhile, continued sinking in that millennium tower. >> has put repair efforts on hold tonight. 100 million dollar project is underway to stop this. san francisco luxury high rise from sinking and tilting more than it has already. but that project is now on hold as engineers try to figure out why the building has sunk another injured during the repairs. a spokesman for the millennium tower says that pyle installations to beef up the building's foundation that's on hold for 2 to 4 weeks now. he adds that the building remains safe. the 58 story tower opened in 2000, 9 residents sued after they learned the building had sunk more than a foot and was tilting. >> there is new evidence that shows serious structural defects and construction failures in the debris of the collapsed. surfside condo in florida. there's new video. this is from federal investigators. it shows faulty concrete d

somebody has to go pharmacy hopping to see if they could get that mrna vaccine from cvs or they haven't have to do that when it is recommended for them based on their risk profile. >> i think i could be wrong, but i think like 12 million meshes received the johnson & johnson mingle dose vaccine. do you think they should now get either the pfizer or the moderna as a booster, as a second dose? >> you know, i agree. this is a place where the fda really has to step in. here's why, wolf. there are a lot of questions about boosters. elderly americans who got vaccinated with the mrna vaccine six months ago may have some waning immunity. we have the johnson & johnson question. every single person trying to figure this out on their own is a really bad idea. so i want to see clear guidance from the fda. i do think some people will end up needing boosters. but i want the fda to weigh in on this and not everybody figure this out on their own. >> we're grateful to both of you as always. and there is more breaking news emerging here in "the situation room" as president biden joins the house speake

and a booster mrna immunization increases antibody titers by multiple fold. all of this supports the use of a third booster mrna immunization to increase the overall level of protection. back to you now, jeff. >> thank you. i want to be clear the whole effort is ready to get every american that needs one a booster shot. pending fda approvals, booster wills be available starting the week of september 20th. the plan is for the rule to be simple. get your booster eight months after you got your second shot. if you got your second shot on february 1st. thanks to the aggressive actions that we have taken to establish our vaccination program it will be just as easy and convenient to get a booster shot as it is to get a first shot today. we have enough vaccine supply for every american. and you will be able to get a booster at roughly 80,000 places across the country including over 40,000 local pharmacies. in fact 90% of americans have a vaccine site within five miles of where they live. and importantly booster wills be free no id or insurance is required. so the bo

biontech had to pivot away from personalized cancer drugs using mrna to focus on this vaccine. remarkable stuff. meg, appreciate it everybody, do not miss that. "a race against covid. you can find the documentary at cnbc.com and cnbc pages as well. worth the tcwah. >>> traders are making more moves in their portfolios. you're going to learn them next on "halftime." growing up in a little red house, on the edge of a forest in norway, there were three things my family encouraged: kindness, honesty and hard work. over time, i've come to add a fourth: be curious. be curious about the world around us, and then go. go with an open heart, and you will find inspiration anew. viking. exploring the world in comfort. >>> all right. your investment committee is making more moves in their portfolio. why are you adding to medtronic? >> so, for me, i was slightly underweight here on medtronic and just added additional capital. i really like their print. i think 19% organic revenue growth, 190 launch new products, which is a record for them i like health care in general. i think preventive car

most of the discussions of boosters around the mrna vaccines. what should folks vaccinated with the johnson & johnson shot, how should they take this information? >> i'm sure it's frustrating to them. the discussions are around the mrna vaccines. i asked about that specifically. they brought up the point that, first o of all, with the johnson & johnson vaccine, it was authorized a few months later than the original vaccines. as a result there's less data and also fewer people who have taken that vaccine, about 22 million or so that have received those shots, so less data overall. having said that, it sounds like there will be some movement on the j&j vaccine as well. they're likely to recommend boosters at some point in the future, within the next couple weeks or so. we'll see. they want to review the data, answer the same questions and make sure they can make the case that it would be safe to give a booster and it would be efficacious. it would have increased effectiveness. as you know, they've been doing this in some places around the world an

fda, cdc and the europeans, for -- to figure out from an arsenal -- the beauty about mrna technology is we can do this response versus conventional biotechnology that takes years and years to do the same thing. david: to get to the problem of my own personal situation i got , two moderna shots. do i need a booster? noubar: i think that the best advice so far is that people after a certain age and i cannot tell you right now what that cut off will be, because that will be set by the government, are most likely going to need a booster to be well protected against the variant. and over time, public health officials will have to decide if everyone should get a booster shot. given enough time, we may end up in a situation where we have yearly, at a minimum, vaccinations just like the flu. david: tony fauci you has said we should use the example of the coronavirus to prepare for other potential viruses down the road, and that companies like yours will do that. are you working on that already? noubar: absolutely. absolutely. a very big part of moderna's future will be in being the leading v

or johnson & johnson vaccines need to be given as a series of three or four shots, say for mrna andor johnson & johnson or if they can remain a two-shot series and a one-shot series respectively with boosters. hepatitis b, tdap as a booster, we don't know exactly yet where covid-19 is going to fall. the data in our country seems to show the percentage of hospitalizations and severe disease has been increasing in breakthrough infections, but the absolute number remains low that the sickest people are still the unvaccinated but we're seeing the numbers creep up in those of us vaccinated. >> hau for your reporting. we'll talk more about this when the covid briefing begins at the top of the hour, 20 minutes from now. i br ing in somebody who knows this very well, dr. richard besser, former acting director of the cdc, now president and ceo of the robert woods foundation. good morning. >> good morning, nice to be here. >> big day, by morning for this, too. talk through number one your overall takeaways here and two on the time line. you think about the questions that many americans might

san francisco general voted on monday to allow the hospitals vaccine clinic to give a supplemental mrna vaccine to somebody who had the j&j shot. >> potential benefit, no downside, to me as we look at the future of what the virus and what we are facing with a 4th search. it does make sense. >> reporter: 665,000 san francisco and have been vaccinated but only about 8% have received the johnson & johnson shot. >> we are worried about breakthrough infections. people were having concerns about whether the single-dose was going to be enough. >> reporter: that concern is why dr. winston says some people has have gone out to get extra vaccine doses on their own. hospital epidemiologist, she supports the supplemental dose but wants to be clear there is not enough data to support any benefit. >> there is not a specific recommendation to give it. it is not part of an emergency use authorization. >> reporter: but you think it is safe? >> yes, we think it's safe. >> reporter: san francisco general is priors icing city residents but the doctor says as long as the clinic has space and vaccines, they

we've never done a vaccine with mrna before.cientifically makes the most sense. it's fascinate to go hear about how they to go about these things early on. >> kudos thanks for bringing us a piece of that. our meg tirrell. you can check out "a race against covid-19" on cnbc.com or youtube. >>> let's get a check on the vaccine makers and how they've done since they received emergency use authorization from the fda. pfizer was the first to receive theirs on december 20th. it's up only about 13% since then moderna approved on december 18th of 2020, up 165% since then of course mrna the technology meg was referencing. and johnson & johnson received its own on february 27th of this year up about 10% in that time still ahead, the retail traders are getting smarter but that could increase the potential for new investors to getburned we're going to dig into what's called the graduation effect xt here's andy listening to my goals and making plans. this is us talking tax-smart investing, managing risk, and all the ways schwab can help me i

but they say that this mrna technology can be used for many different vaccines in the future for now live in san francisco. i'm taylor. the second reporting kron 4 news. >> appreciated. taylor. meanwhile, now to our wildfire coverage. and crews are trying to prevent this massive caldor fire from spreading into more populated areas. you see this aerial footage here shows that some of the scale of just how big this thing is in eldorado county. this is the eldorado national forest making water drops retardant, drops phys grown more than 136,000 acres since it started about a week and a half ago. that's 4 times the size of san francisco. more than 450 homes have been destroyed with about 17,000 homes. still threatened tonight. really trying to keep this out of the tahoe basin. but that is a battle right now. the fire is just 12% contained the closure of highway 50 has been extended and folks in south lake tahoe, tourism. people who, you know, really need tourists to come there saying stay away right now air is just so bad and then added need those roads clear so that first responders fir

the mrna technology would -- technology which has been the most effective.thers that have reviewed these contracts suggest a u.s. government has the ability to hunt fairly strongly the manufacturer to engage in these kind of activities. so therefore, this is an opportuny -- there's this need to expand the production of the mrna vaccines, especially the ones developed through substantial u.s. government, intellectual and financial investment. the u.s. should engage in tenology transfer. laura: it is being reported the fda's about to authorized booster shots for immuno come from eyes to people. how does that strike you when there is so much need in the world? -- immunocompromised people. how does that strike you, when there is so much need in the world? >> when it comes to immuno come from eyes individuals, i as a scientist -- immunocompromised individuals, i as a scientist think there is evidence to consider it for a limited number of folks, where we know their response could use a third dose. i don't think this is an either or situation. especially when it c

they have not de-risk mrna, but also the delivery.get a drug into the human body and go where it needs to go. they are proving their technology is able to work with the covid vaccine. other therapies of their state utilize the technology are also slightly de-risk. matt: the analyst recommendations page on the bloomberg shows the 12 month price target is $207. the last price was $420. more than double the price target. why isn't the analyst community more excited? >> many will argue that the company has had its run. they're looking at just the coronavirus still part of the story. they are not looking at the much larger part of the story. once you realize that this is a fully automated digitized ai enabled platform, it gives you a long tail of growth over the next decade. amanda: there's a lot of renewed interest in the health care space. we talk about the investing horizon, what is your thinking process or how long do you have to be in it to justify investment in the space? >> in general, we are not just looking at therapeutics, we are

san francisco general voted on monday to allow the hospitals vaccine clinic to give a supplemental mrna vaccine to somebody who had the j&j shot. >> potential benefit, no downside, to me as we look at the future of what the virus and what we are facing with a 4th search. it does make sense. >> reporter: 665,000 san francisco and have been vaccinated but only about 8% have received the johnson & johnson shot. >> we are worried about breakthrough infections. people were having concerns about whether the single-dose was going to be enough. >> reporter: that concern is why dr. winston says some people has doses on their own. hospital epidemiologist, she supports the supplemental dose but wants to be clear there is not enough data to support any benefit. >> there is not a specific recommendation to give it. it is not part of an emergency use authorization. >> reporter: but you think it is safe? >> yes, we think it's safe. >> reporter: san francisco general is priors icing city residents but the doctor says as long as the clinic has space and vaccines, they will give the mrna supplement to pe

chris colewell first shared the news about the extra mrna vaccine on abc7. >> i was concerned, becauseit has been an issue for a while. >> reporter: they are not recommending the extra dose, but rather accommodate special requests. >> i'm very support inof san francisco general's decision to allow people that got the johnson & johnson shot to get one of the mrna shots as a booster. >>> despite what the cdc and the white house said today? >> and i'm not necessarily disagreeing with what they're saying. they are say there is not data saying taw have to do this, and i agree with that. >> reporter: some wanted to know how the hospital came to its decision and addressed concerned about liability. >> but there's a lot of places that are thinking about this. the new york department of public health is one of many. the evidence that we have suggests it may help it and won't hurt, and doesn't it make sense to just consider this. >> reporter: the extra shots are expected to be available in the next week at san francisco general. >>> new york is set to become the first city in the country to requ

they say we could see a lot more uses of this mrna technology. to lead the psac ii kron 4 news. >> 6.51 and the leaning tower of san francisco is still leaning in the repairs are on hold. the sinking millennium tower is a problem because the project they had to stop it for a while. the luxury high rise has been tilting, as you know, and they're trying to fix its cars about a 100 million dollars. but they had to pause because the engineers are trying to figure out why even during their fixing work. it still has gone down. another rich. a spokesperson for the millennium tower says that the pyle insulation to beef up the foundation is on hold now for 2 to 4 weeks. he adds the building still remain safe. it's leaning the 58 story tower opened in 2009 and residents sued shortly after they learned that the building had some more than a foot and it was tilting. >> all right. we'll take a break. it's 6.52. coming up, the giants sweep the mets on the road as they stay ahead of the dodgers in the nl west. we'll have highlights in just a minute. ♪ ♪ ♪ ♪ ♪ ♪